'Measuring Innovation – a brief introduction to the REMEDiE project' – Michael Morrison

November 26, 2009

“Innovative health technologies: health systems in transition Workshop”

Supported by: Internet Interdisciplinary Institute (IN3)

Organized by: Francisco Lupiáñez-Villanueva (Internet Interdisciplinary Institute –UOC) and Michael Hardey (Hull/York Medical School – Science and Technology Studies Unit, Department of Sociology, University of York)

Data: 26th and 27th November

Place: UOC IN3 building. Av. Canal Olímpic, s/n. Edifici B3, 08860 Castelldefels (Barcelona)

Michael Morrison’s presentation – ‘Measuring Innovation – a brief introduction to the REMEDiE project’

In this presentation I will introduce my current work on the Regenerative Medicine in Europe (REMEDiE) project. I aim to describe how we have set about trying to measure and assess European commercial activity in regenerative medicine – including stem cells, gene therapy and tissue engineering. I will discuss some of the difficulties we faced in finding ways to appropriately measure this activity in line with the goals of the work package and provide some details of the different approaches we have employed so far. Much of what I discuss is work in progress so I hope to get some useful and stimulating feedback.

Michael Morrison

Currently working on the FP-7 funded REMEDiE project  at the Science and Technology Studies Unit (SATSU) at York, investigating the networks of commercial innovation in regenerative medicine with a specific focus on European biotechnology. Other research interests include the emergence of new (bio)medical technologies and associated issues including, social shaping of technologies, history of medicine and medical technology, and
(sociology of) bioethics, especially with regards to human enhancement and the commercial application(s) of human tissue-derived products.